What Happened?

Shares of healthcare diagnostics company Quest Diagnostics (NYSE: DGX) jumped 6.4% in the morning session after the company reported strong second-quarter financial results that beat Wall Street expectations and raised its full-year guidance. 

The medical laboratory operator announced second-quarter revenues of $2.76 billion, a 15.2% increase from the same period last year. This figure surpassed analysts' forecasts of $2.72 billion. Earnings also came in ahead of expectations, with adjusted earnings per share (EPS) of $2.62, beating the average analyst estimate of $2.57. The strong performance was driven by a 16.3% increase in testing volume, which included a 2.1% rise in organic volume, indicating solid underlying demand for its services. The company also highlighted growth from acquisitions and expanded business from enterprise accounts. Buoyed by these results, Quest Diagnostics raised its full-year 2025 forecast. It now expected revenues to be between $10.80 billion and $10.92 billion, and adjusted EPS to be in the range of $9.63 to $9.83.

Is now the time to buy Quest? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Quest’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

Quest is up 16.3% since the beginning of the year, and at $175.54 per share, it is trading close to its 52-week high of $182.07 from June 2025. Investors who bought $1,000 worth of Quest’s shares 5 years ago would now be looking at an investment worth $1,353.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.